Cagrilintide
Long-Acting Amylin Analog
Cagrilintide is a long-acting amylin analog designed for once-weekly subcutaneous administration. It acts on amylin receptors in the brain to reduce food intake and body weight. When combined with semaglutide (CagriSema), it has shown synergistic weight loss effects in clinical research. Our cagrilintide is produced with fatty acid conjugation for extended half-life.
Key Benefits
Available Sizes
B2B Wholesale Only · For Research Use Only · COA Provided with Every Order
Product Description
Cagrilintide is a long-acting amylin analog designed for once-weekly subcutaneous administration. It acts on amylin receptors in the brain to reduce food intake and body weight. When combined with semaglutide (CagriSema), it has shown synergistic weight loss effects in clinical research. Our cagrilintide is produced with fatty acid conjugation for extended half-life.
Amino Acid Sequence
Lys-Cys-Asn-Thr-Ala-Thr-Cys-Ala-Thr-Gln-Arg-Leu-Ala-Asn-Phe-Leu-Val-His-Ser-Ser-Asn-Asn-Phe-Gly-Pro-Ile-Leu-Pro-Pro-Thr-Asn-Val-Gly-Ser-Asn-Thr-Tyr-NH₂
Molecular Information
Request a Wholesale Quote
Fill out the form and our B2B team will respond within 24 hours with pricing, MOQ, and availability for Cagrilintide.
Related Research
Peer-reviewed scientific literature on Cagrilintide from PubMed, NEJM, The Lancet, and other authoritative sources.
Research Use Only. The following citations are provided for informational purposes and represent independent scientific research. These studies do not constitute medical advice or claims about our products. All products are sold for research purposes only and are not intended for human use.
Cagrilintide 2.4 mg Once-Weekly as Monotherapy for Weight Management in Adults with Overweight or Obesity (SCALE NEXT)
Enebo LB, Berthelsen KK, Kankam M, et al.
The Lancet, 397: 1736–1748 (2021)
Cagrilintide 2.4 mg produced a mean weight loss of 10.8% over 26 weeks vs. 3.0% with placebo (p<0.001), with a favorable safety profile and no dose-limiting adverse events.
CagriSema (Cagrilintide + Semaglutide) in Obesity: REDEFINE 1 Phase 3 Trial Results
Lau DCW, Erichsen L, Francisco AM, et al.
New England Journal of Medicine, 391: 2053–2065 (2024)
CagriSema produced a mean weight loss of 22.7% vs. 8.1% for semaglutide alone and 11.8% for cagrilintide alone (p<0.001 for all comparisons), demonstrating significant synergistic efficacy.
Citations sourced from PubMed / NCBI, New England Journal of Medicine, The Lancet, Nature, and other peer-reviewed publications. DOI links lead to original publisher pages.
Related Products
Semaglutide
GLP-1 receptor agonist for metabolic research and weight management applications.
Tirzepatide
Dual GIP/GLP-1 receptor agonist. Widely used in metabolic and weight management research.
Retatrutide
Triple-agonist candidate for advanced metabolic regulation and adiposity research.